Aminorex to fen/phen: An epidemic foretold

Circulation

Volumn 99, Issue 1, 1999, Pages 156-161

  Fishman, Alfred P ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anorexigens; Drugs; Nearotransmitters; Obesity; Pharmacokinetics

Indexed keywords

AMINOREX; ANOREXIGENIC AGENT; BIGUANIDE DERIVATIVE; CHLORPHENTERMINE; DEXFENFLURAMINE; FENFLURAMINE; MONOCROTALINE PYRROLE; PHENFORMIN; RAPESEED OIL; SEROTONIN; TRYPTOPHAN;

DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; EOSINOPHILIA MYALGIA SYNDROME; HUMAN; LACTIC ACIDOSIS; LIVER DISEASE; NEUROTRANSMISSION; OBESITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; TOXIC OIL SYNDROME; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

EID: 0033547771     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.1.156     Document Type: Review

References (56)

1. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with flenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
2. Voelkel NF, Clarke WR, Higenbottam TW. Obesity, dexfenfluramine and pulmonary hypertension: a lesson not learned? Am J Respir Crit Care Med. 1997;155:786-788.
3. Fishman AP. N Engl J Med. 1997;336:511. Letter.
4. Fishman AP. Dietary pulmonary hypertension. Circ Res. 1974;35: 657-660.
5. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med. 1997; 336:407.
6. Greiser E. Epidemiologische Untersuchungen zum zusammenhang swischen appetitzueglere innahme und primaer vasculaer pulmonaler hypertonie. Internist. 1973;14:437-442.
7. Gurtner HP. Aminorex pulmonary hypertension. In: Fishman AP. The Pulmonary Circulation: Normal and Abnormal. Philadelphia, Pa: University of Pennsylvania Press; 1990:397-412.
8. Mielke H, Seiler KU, Stumpf U, Wasserman O. Influence of aminorex (menocil) on pulmonary pressure and on the content of biogenic amines in the lungs of rats. Naunyn Schmiedebergs Arch Pharmacol. 1972; 274(suppl):R79. Abstract.
9. Kay JM, Heath D. Crotalaria Spectablis: Pulmonary Hypertension Plant. Springfield, Mo: Charles C. Thomas; 1969:1-136.
10. Wagner J-G, Petty TW, Roth RA. Characterization of monocrotaline/ pyrrole-induced DNA cross-linking in pulmonary artery endothelium. Am J Physiol. 1993;264:L517-L522.
11. Zhu L, Wigle D, Hinek A, Kobayashi J, Ye C, Zuker M, Dodo H, Keeley FW, Rabinovitch M. The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats as a novel enzyme related to the serine-proteinase adipsin. J Clin Invest. 1994;94:1163-1171.
12. Sitbon O, Brenot F, Hervé P, Parent F, Azarian R, Taravella O, Simonneau G. Pulmonary hypertension associated with portal hypertension: comparison with primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151:A723. Abstract.
13. Groves BM, Brundage BH, Elliott CG, Koerner SK, Fisher JD, Peter RH, Rich S, Kernis J, Dantzker DR, Fishman AP, Moser KM, Pietro DA, Reeves JT, Rounds SIS. Pulmonary hypertension associated with hepatic cirrhosis. In: Fishman AP, The Pulmonary Cirulcation: Normal and Abnormal. Philadelphia, Pa: University of Pennsylvania Press; 1990: 359-370.
14. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis. 1983;127:437-441.
15. Kilboume EM, Rigau-Perez JG, Heath CW Jr, Zack, MM, Falk, H, Martin-Marcos, M, deCarlos, A. Clinical epidemiology of toxic-oil syndrome: manifestations of a new illness. N Engl J Med. 1983;309: 1408-1414.
16. Garcia-Dorado D, Miller DD, Garcia EJ, Delca J-L, Marota E, Chaitman BR. An epidemic of pulmonary hypertension after toxic rapeseed oil ingestion in Spain. J Am Coll Cardiol. 1983;1:1216-1222.
17. López-Sendón J, Gomez Sanchez MA, Mestre de Juan MJ, Coma-Canella I. Pulmonary hypertension in the toxic oil syndrome. In: Fishman AP, The Pulmonary Cirulcation: Normal and Abnormal. Philadelphia, Pa: University of Pennsylvania Press; 1990:385-395.
18. Amaiz-Villena A, Martinez-Laso J, Corell A, Allende L, Rosal M, Gomez-Reino JJ, Vicario JL. Frequencies of HLA-A24 and HLA-DR4-DQ8 are increased and that of HLA-B blank is decreased in chronic toxic oil syndrome. Eur J Immunogen. 1996;23:211-219.
19. Fahlén M, Bergman H, Helder G, Rydén, L, Wallentin, I, Zettergren, L. Phenformin and pulmonary hypertension. Br Heart J. 1973;35:824-828.
20. Clinical spectrum of eosinophila-myalgia syndrome: California. MMWR. Morb Mortal Wkly. 1990;112:85-87.
21. Martin RW, Duffy J, Engel AG, Lie JT, Bowles CA, Moyer TP, Gleisch GJ. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion: clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med. 1990;113:124-134.
22. Varga J, Uitto J, Jimenez SA. The cause and pathogenesis of the eosinophilia-myalgia syndrome. Ann Intern Med. 1992;116:140-147.
23. Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M, Gleich GJ. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med. 1990;322:869-873.
24. Silver RM, Heyes MP, Maize JC, Quearry B, Vionnet-Fuasset M, Sternberg EM. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med. 1990;322:874-881.
25. Philen RM, Hill RH. Pulmonary hypertension in patients with eosinophilia-myalgia syndrome or toxic oil syndrome. Mayo Clin Proc. 1993;68:823-824.
26. McGoon MD, Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest. 1984;74:828-833.
27. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A. 1986;83:674-678.
28. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. Pulmonary hypertension and fenfluramine. BMJ. 1981;283:881-883.
29. Roche N, Labrune S, Braun JM, Huchon G. Pulmonary hypertension and dexfenfluramine. Lancet. 1992;339:436-437. Letter.
30. Brenot F, Hervé P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J. 1993; 70:537-541.
31. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335:609-616.
32. Manson JE, Faich GA. Pharmacotherapy for obesity: do the benefits outweigh the risks? N Engl J Med. 1996;335:659-660. Editorial.
33. Food and Drug Administration, Endocrinologie and Metabolic Drugs Advisory Committee Meeting of September 25, p 148, 1995.
34. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:635. Letter.
35. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984;144:1143-1148.
36. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L. Long-term weight control study V (weeks 190 to 210): follow-up of participants after cessation of medication. Clin Pharmacol Ther. 1992; 51:615-618.
37. Heuer J. Pulmonary hypertension. Chir Prax. 1978;23:497. Abstract.
38. Eicholtz F, Vemey EB. On some conditions affecting the perfusion of isolated mammalian organs. J Physiol. 1924-1925;59:340-344.
39. Gaddam JH, Hebb CO, Silver A, Swan AAB. 5-Hydroxytryptamine. Pharmacological action and destruction in perfused lungs. Q J Exp Physiol. 1953;38:255-262.
40. Thomas DP, Vane JR. 5-Hydroxytryptamine in the circulation of the dog. Nature. 1967;216:335-338.
41. Junod AF. 5-Hydroxytryptamine and other amines in the lung. In: Fishman AP, Fisher AB, eds. Handbook of Physiology: The Respiratory System. Bethesda, Md: American Physiology Society; 1985;1:337-350. Section 3.
42. Fishman AP, Pietra GG. Handling of bioactive materials by the lung. N Engl J Med. 1974;29:884-890,953-959.
43. Fisher AB, Pietra GG. Comparison of serotonin uptake from the alveolar and capillary spaces of isolated rat lung. Am Rev Respir Dis. 1981;123: 74-78.
44. Angevine LS, Mehendale HM. Effect of chlorophentermine on the pulmonary disposition of 5-hydroxytryptamine in the isolated perfused rabbit lung. Am Rev Respir Dis. 1980;122:891-898.
45. Morita T, Mehendale HM. Effects of chlorphentermine and phentermine on the pulmonary disposition of 5-hydroxytryptamine in the rat in vivo. Am Rev Respir Dis. 1983;127:747-750.
46. Tornebrandt K, Eskilsson J, Nobin A. Heart involvement in metastatic carcinoid disease. Clin Cardiol. 1986;9:13-19.
47. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, Feldman JM. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995;92:790-795.
48. Millward MJ, Blake MP, Byrne MJ, Hung J, Gibson P. Left heart involvement with cardiac shunt complicating carcinoid heart disease. Aust N Z J Med. 1989;19:716-717.
49. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 1988;77: 264-269.
50. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pilot HC, Kvois LK. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188-1196.
51. Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med. 1997;337:602-606.
52. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation. 1970;42:1163-1184.
53. Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, Archer SL. Anorectic agents aminorex, fenfluramine and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 1996;94:2216-2220.
54. Gloster J, Heath D, Haselton P, Harris P. Effect of chlorphentermine on the lipids of rat lungs. Thorax. 1976;31:558-564.
55. Hervé P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L. Increased plasma serotonm in primary pulmonary hypertension. Am J Med. 1995;99:249-254.
56. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA III, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;152:93-97.